MedTrace Logo

Different Fluorescein Sodium Dosage for the Detection of Gastric Intestinal Metaplasia

NCT02534818 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 180

Last updated 2015-11-10

No results posted yet for this study

Summary

The purpose of this study is to assess whether lower fluorescein sodium dosage can perceive the same detection rate per patient and per lesion for the detection of gastric intestinal metaplasia.

Conditions

  • Gastric Intestinal Metaplasia

Interventions

DRUG

lower fluorescein sodium dosage 0.02ml/kg

fluorescein Sodium Dose of 0.02ml/kg on gastric intestinal metapalsia

DRUG

conventional fluorescein sodium dosage 0.1ml/kg

fluorescein Sodium Dose of 0.1ml/kg on gastric intestinal metapalsia

Sponsors & Collaborators

  • Shandong University

    lead OTHER

Principal Investigators

  • Yanqing Li, PhD. MD · Department of Gastroenterology, Qilu Hospital, Shandong University

Study Design

Allocation
RANDOMIZED
Purpose
DIAGNOSTIC
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
40 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-06-30
Primary Completion
2015-11-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02534818 on ClinicalTrials.gov